Silk Road Medical
10
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
20.0%
2 terminated/withdrawn out of 10 trials
80.0%
-6.5% vs industry average
10%
1 trials in Phase 3/4
75%
6 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
ROADSTER 3 Extended Follow-up Sub-Study
Role: lead
The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Evaluation
Role: lead
Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease
Role: lead
Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System
Role: lead
The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Study
Role: lead
POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE
Role: lead
Silk Road Medical First in Man Study - Neuroprotection During Carotid Stenting and Angioplasty
Role: lead
The MICHI NEUROPROTECTION SYSTEM: Evaluation of Performance in Carotid Artery Stent Procedures (The LOTUS Study)
Role: lead
Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure
Role: lead
MICHI™ Neuroprotection System (NPS+f) Filter Debris Analysis Study (The F-1 Study)
Role: lead
All 10 trials loaded